Briefings and threat intelligence on the counterfeit landscape — from falsified medicines to the networks behind luxury fakes. Considered, evidence-led, and free of hype.
Why counterfeit GLP-1 and weight-loss medicines have become a patient-safety crisis — and how manufacturers can respond.
Read the briefing →
The economics of counterfeiting, and why network disruption beats takedown volume every time.
Read the briefing →
How counterfeits move through the world's free-trade hubs — and where interception works best.
Read the briefing →
A suspected counterfeit semaglutide product identified through monitoring, preserved under chain of custody, independently laboratory-tested, and referred to the relevant regulator — with the wider network mapped for the brand owner. Details are illustrative; real casework is strictly confidential.
Occasional, substantive threat intelligence for brand-protection, security and legal teams. No noise.
Request the briefings